Patients using a smart insulin pump system made by Medtronic (NYSE:MDT) spent more time in a healthy blood glucose range, according to real-world data from more than 8 million patient days.
The MiniMed 670G is designed to automatically track and adjust blood sugar levels, using a continuous glucose monitor, guiding patients toward a minimum level of 120 mg/dL. Medtronic first won FDA approval for the MiniMed 670G in September 2016.
Get the full story on our sister site, Drug Delivery Business.
